Does the time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery affect outcomes for locally advanced esophageal squamous cell carcinoma?

ConclusionsLocally advanced ESCC patients with time interval from neoadjuvant camrelizumab combined with chemotherapy to surgery > 8 weeks were associated with worse long-term survival.

http://link.springer.com/10.1007/s00432-024-05696-4

Source: Journal of Cancer Research and Clinical Oncology - March 27, 2024 Category: Cancer & Oncology Source Type: research